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greatest in patients with the largest infarcts. Further, pa-
tients older than 60 years of age had a much greater
tendency to remodel than younger patients.
COMPUTED TOMOGRAPHY
Noninvasive coronary angiography has long been one of the
holy grails of non-invasive imaging. Two studies (17,18)
reported the initial experience with coronary angiography
obtained with 16-slice computed tomography and demon-
strated the feasibility of delineating stenosis in vessels as
small as 1.5 mm. Using conventional cineangiography as a
gold standard, both groups demonstrated sensitivities of
88% to 90% and specificities of 90% to 95%. A representa-
tive image provided by Dr. Schroeder (17) is shown in
Figure 3.
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Valvular heart disease was the focus of many exciting
presentations at the American College of Cardiology Sci-
entific Sessions in 2003. Traditional concepts related to
“degenerative” native and prosthetic valve disease are being
challenged, our surgical approaches are improving, and we
are beginning to see over the horizon at the possibilities for
percutaneous approaches to valve replacement and repair.
The role for cholesterol and inflammation in the devel-
opment of calcific aortic stenosis (AS) continues to evolve.
An estimated 2% to 9% of the elderly have calcific AS (1,2),
and they share both similar risk factors with those suffering
from atherosclerosis (3,4) and pathophysiologic mecha-
nisms that result in calcification (5). Of the many abstracts
investigating this, Fondard et al. (6) presented evidence for
an increase in matrix metalloproteins in AS. Matrix metal-
loproteins are proteolytic enzymes that lead to the degrada-
tion of the extracellular matrix; overexpression has been
associated with a variety of processes, most notably osteo-
arthritis (7). That tumor necrosis factor (TNF)-alpha may
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also be implicated was suggested by Kaden et al. (8). In this
latter study, explanted aortic valve cells grown in culture
treated with TNF-alpha resulted in an increase in the
expression of osteoblast-associated genes and calcification.
There remains hope that medical therapy may slow the
progression of, or prevent, AS. A recent editorial in the
Journal addresses the issue (9). The AS valvular tissue
harbors chronic infiltrations of macrophages, T lympho-
cytes, low-density lipoproteins, lipoprotein(a), osteopontin
(a mediator of calcification), angiotensin-converting enzyme
(ACE), and angiotensin II (10). Retrospective studies
(11–15) have provided encouraging results regarding the
effects of statins. However, in another retrospective echo-
cardiographic study (16), 95 patients with AS on statins
were compared with a similar AS cohort not on statins at a
mean follow-up of 51 months, and no difference in the rate
of change of the valve gradient, aortic valve area, symptoms,
or need for aortic valve replacement (AVR) was found
between the groups. Because ACE has been identified in
AS valvular lesions, Olsen et al. (17) reviewed the effect of
losartan compared with atenolol in 960 patients randomized
in the Losartan Intervention for Endpoint reduction in
hypertension (LIFE) study. Unfortunately, AS progressed
regardless of the treatment arm.
There were many interesting surgical presentations re-
garding valvular disease. What to do with the mitral
regurgitation (MR) in patients undergoing isolated AVR
was addressed by Diodato et al. (18). In a retrospective
echocardiographic review, with a mean follow-up of 16
months after AVR, the MR often persisted regardless of the
baseline severity. The authors concluded that even mild to
moderate MR should be repaired at the time of AVR,
though no other supportive evidence was presented in this
regard.
The risk associated with MR surgery in patients under-
going coronary artery bypass graft surgery (CABG) was
reviewed using the Society of Thoracic Surgery’s database
(19). The 30-day data from 4,137 patients with an ejection
fraction 35% and associated MR revealed that mortality
for CABG alone was 9.2%. Mortality from CABG plus
mitral annuloplasty was 8.4%, CABG plus mitral repair was
7.7%, and CABG plus mitral valve replacement (MVR) was
14.3%. Thus, in these patients, mitral annuloplasty or repair
added no additional risk to CABG, but MVR worsened
early survival. Longer term follow-up data were not pre-
sented.
There remains an interest in novel prosthetic material for
valve replacement. In a study of 11 patients undergoing the
Ross procedure (20), excellent hemodynamic results using a
tissue-engineered valve in the pulmonic position were re-
ported. Four weeks before surgery, forearm or saphenous
venous cells were harvested and grown in a tissue laboratory.
These cells then seeded a decellularized pulmonary allograft
coated with basal membrane glycoproteins. The patients
were followed for two years with no evidence for early
pulmonary homograft restenosis found.
Finally, Cribier et al. (21) reviewed the data that led to
the first human percutaneous AVR reported in 2002 (22)
describing two additional patients in whom the procedure
had been successful. The valve consisted of three bovine
pericardial leaflets mounted into a stainless steel balloon
expandable stent. A different approach taking advantage of
the valve in the bovine jugular vein has been described by
Boudjemline and Bonhoeffer (23).
Percutaneous approaches to MR were the subject of a
session with Drs. Pandian and Fitzgerald. They noted that
Dr. Jose Candado from Venezuela had successfully per-
formed the first human insertion of a coronary sinus MR
reduction device.
In summary, the pathophysiology of what is traditionally
considered “degenerative” aortic valve disease remains of
great interest. The desperate need for appropriately de-
signed and executed randomized trials to investigate treat-
ment options, such as statins and ACE inhibitors, remains
obvious given the mixed results of retrospective trials. When
AVR is being performed, the presence of associated MR
may warrant concurrent repair. When CABG is performed
in patients with poor left ventricular function and MR,
mitral repair or annuloplasty does not add to early mortality,
but MVR does. Tissue-engineered valves appear promising,
at least when used in the pulmonary position in the Ross
procedure. And finally, the meetings provided the first
glimpse for the attendees at the possibilities for percutane-
ous valve replacement and repair.
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Cardiac Function and Heart Failure
Marc A. Pfeffer, MD
Boston, Massachusetts
I had the pleasure working with Drs. Jonathan Abrams,
Howard A. Cohen, Sudhir S. Kushwaha, and Eric S.
Williams to develop the specific contributions in the broad
field of cardiac function and heart failure to be presented as
original work at these Scientific Sessions. With the assis-
tance of other highly respected reviewers, 1,143 abstracts
were graded for selection for only 351 allotted slots on the
overall program. As such, many highly ranked abstracts
were not able to be accepted for presentation. The accepted
abstracts were then assigned into thematically grouped
sessions. Although it is impossible to cover the content of
these original contributions, a brief overview of the titles of
these sessions provides some insight into the active areas of
investigation.
There were several sessions devoted to cardiomyopathies
with specific sessions for hypertrophic, dilated, and re-
stricted cardiomyopathies. The Program Committee also
had one session termed miscellaneous cardiomyopathies.
This does not indicate that the Program Committee iden-
tified a new form of cardiomyopathy, but does demonstrate
that there were many highly ranked abstracts on the issue of
cardiomyopathy that did not quite fall into one of the easily
recognized clinical patterns. Myocarditis continues to be an
important area of investigation.
Contributions concerning cardiac transplantation pro-
duced several high-quality sessions concentrating on clinical
prognostic factors for both short-term rejection and allo-
graft vasculopathy. It is noteworthy that two entire sessions
were devoted to the left ventricular assist device, providing
a flavor of the advances in this field in managing these
highest risk patients.
A substantial proportion of the accepted presentations
concentrated on the interface of cardiac function, heart
failure, and the elderly. There were particular sessions
devoted to physiologic alterations, coronary syndromes, and
specific risk factors for failure in the elderly as well as the
risk/benefits of pharmacologic therapy in this important
segment of our population. My favorite session topic was
entitled “Hazards of Being Elderly.” Although I did not
attend the specific session, I was assured that an American
Association of Retired Persons card was not required for
admission.
The number of abstract submissions and acceptances
concerning heart failure with preserved systolic function
indicates that this is a clear investigative growth area.
Exercise testing as well as exercise training continue to be
important investigative and therapeutic areas. Contributions
concerning ventricular remodeling continue to provide
mechanistic underpinnings for a broad range of areas of
cardiac function and heart failure. The prognostic impor-
tance of old standards, such as assessments of left ventricular
as well as right ventricular ejection fractions, was empha-
sized in several sessions concerning outcomes of patients
with heart failure.
The added prognostic value of a determination of B-type
natriuretic peptide (BNP) levels was a clear theme across a
strong group of accepted abstracts. Important contributions
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